- Guide to PHARMACOLOGY
Synonyms: compound 23 [PMID: 30113844] | PF-06700841 | PF06700841
Compound class: Synthetic organic
Comment: Brepocitinib (PF-06700841) is a dual Janus kinase 1 (JAK1) and TYK2 inhibitor . It is proposed for treating autoimmune and other inflammatory conditions. Brepocitinib is a Type 1 ATP site inhibitor.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|PF-06700841's JAK1/TYK2 selectivity profile is designed to guard against JAK2 driven hematopoietic changes that are evident for pan-JAK inhibitors.|